96225-49-9 Usage
Description
3-CHLORO-6-(2-METHYLPHENYL)-PYRIDAZINE is a chlorinated pyridazine derivative with the molecular formula C11H8ClN3. It features a 3-chloro group and a 2-methylphenyl group, and is recognized for its high stability and low toxicity. This chemical compound is a valuable building block in the synthesis of various organic compounds, particularly in the pharmaceutical and agrochemical industries.
Uses
Used in Pharmaceutical Industry:
3-CHLORO-6-(2-METHYLPHENYL)-PYRIDAZINE is used as a key building block for the synthesis of pharmaceutical drugs. Its unique structure allows for the development of new medications with potential applications in treating various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-CHLORO-6-(2-METHYLPHENYL)-PYRIDAZINE is utilized as a precursor in the creation of agrochemicals. Its incorporation into these products can contribute to enhanced crop protection and management solutions.
Used in Research and Development:
3-CHLORO-6-(2-METHYLPHENYL)-PYRIDAZINE is also used as a research chemical for exploring its potential biological activities. Studies have indicated that it may possess anti-inflammatory and anti-cancer properties, making it a promising candidate for further investigation and development in the medical field.
Check Digit Verification of cas no
The CAS Registry Mumber 96225-49-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,6,2,2 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 96225-49:
(7*9)+(6*6)+(5*2)+(4*2)+(3*5)+(2*4)+(1*9)=149
149 % 10 = 9
So 96225-49-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H9ClN2/c1-8-4-2-3-5-9(8)10-6-7-11(12)14-13-10/h2-7H,1H3
96225-49-9Relevant articles and documents
Cobalt-catalysed C–H methylation for late-stage drug diversification
Ackermann, Lutz,Friis, Stig D.,Johansson, Magnus J.
, p. 511 - 519 (2020/06/05)
The magic methyl effect is well acknowledged in medicinal chemistry, but despite its significance, accessing such analogues via derivatization at a late stage remains a pivotal challenge. In an effort to mitigate this major limitation, we here present a strategy for the cobalt-catalysed late-stage C–H methylation of structurally complex drug molecules. Enabling broad applicability, the transformation relies on a boron-based methyl source and takes advantage of inherently present functional groups to guide the C–H activation. The relative reactivity observed for distinct classes of functionalities were determined and the sensitivity of the transformation towards a panel of common functional motifs was tested under various reaction conditions. Without the need for prefunctionalization or postdeprotection, a diverse array of marketed drug molecules and natural products could be methylated in a predictable manner. Subsequent physicochemical and biological testing confirmed the magnitude with which this seemingly minor structural change can affect important drug properties. [Figure not available: see fulltext.]
